tiprankstipranks
Trending News
More News >
Cresco Labs (TSE:CL)
:CL

Cresco Labs (CL) AI Stock Analysis

Compare
193 Followers

Top Page

TS

Cresco Labs

(OTC:CL)

Rating:51Neutral
Price Target:
C$0.50
▼(-33.33%Downside)
Cresco Labs shows promise with strategic market expansions and improving cash flows, but faces challenges with revenue declines and high leverage. Technical indicators suggest bearish momentum, and valuation metrics indicate potential overvaluation, keeping the overall score moderate.
Positive Factors
Cash Flow
Cresco Labs generated positive operating cash flow of $30.5M in the quarter and finished the period with its highest cash balance in three years.
Growth Prospects
Cresco’s vertically integrated operations in markets such as Ohio, Pennsylvania, and Florida are expected to drive growth into 2025 and beyond alongside new markets like Kentucky.
Negative Factors
Gross Margin
Adjusted EBITDA was slightly below forecast, as lower gross margin translated into lower EBITDA margin.
Revenue Decline
Cresco reported Q1 revenue of $165.8M, down 5.8% sequentially and down 10.1% year-over-year.

Cresco Labs (CL) vs. iShares MSCI Canada ETF (EWC)

Cresco Labs Business Overview & Revenue Model

Company DescriptionCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of December 6, 2022, it owned and operated 55 dispensaries. The company was founded in 2013 and is headquartered in Chicago, Illinois.
How the Company Makes MoneyCresco Labs generates revenue through multiple streams centered around the cannabis market. The primary source of revenue is the sale of cannabis products, which includes flower, edibles, concentrates, and vapes. These products are sold through both wholesale channels to dispensaries and retail operations at the company's owned and operated dispensaries. Additionally, Cresco Labs earns income through licensing agreements for its branded products, allowing other businesses to produce and sell under its well-known brands. The company also benefits from strategic partnerships and acquisitions that expand its market presence and operational capabilities, enhancing its ability to generate revenue across different states. Regulatory compliance and operational efficiency are significant factors contributing to its earnings potential in the highly competitive cannabis industry.

Cresco Labs Earnings Call Summary

Earnings Call Date:May 30, 2025
(Q1-2025)
|
% Change Since: -19.35%|
Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment Neutral
Cresco Labs demonstrated strong cash flow and strategic market expansion, maintaining leadership in key markets and innovating product offerings. However, revenue declines, margin pressures, and challenges from regulatory transitions present concerns. Overall, the highlights are significant but balanced by notable challenges.
Q1-2025 Updates
Positive Updates
Strong Cash Flow and Balance Sheet
Cresco Labs generated $30 million in operating cash flow and ended the quarter with $162 million in cash, marking the highest cash balance in the past three years.
Strategic Market Expansion
Cresco Labs is expanding its footprint by opening new dispensaries in Pennsylvania and Ohio, and building a major cultivation facility in Kentucky, demonstrating a focus on long-term growth in high-margin states.
Leading Market Share in Key States
Cresco Labs retained number one market share positions in Illinois and Pennsylvania and maintained a top-five position across all limited licensed wholesale markets.
Innovation in Product Offerings
Cresco Labs introduced nearly 40 unique new flavors and next-generation premium vapes, along with new hardware and formats for high supply vapes and edibles.
Strong Retail Performance
Sunnyside dispensaries generated approximately 25% more revenue per store than the state average, with 80% of transactions coming from Sunnyside.shop.
Negative Updates
Revenue Decline Concerns
Total retail revenue was down 5% from Q4 due to seasonality and increased competition, while wholesale revenue declined due to a strategic reduction of sales to accounts with credit risks.
Margin Pressure and Competition
Cresco Labs experienced margin pressure with adjusted gross margin down 20 basis points sequentially due to price compression and increased competition, particularly in Illinois.
Impact of Seed-to-Sale System Transition
The mandatory seed-to-sale system conversion in Illinois is expected to impact Q2 revenue as retailers hold off on purchases, leading to onetime impacts on wholesale sales.
Company Guidance
In the first quarter of 2025, Cresco Labs delivered $166 million in revenue, aligning with their guidance by strategically managing their wholesale accounts and reducing accounts receivable exposure. The company achieved an adjusted gross profit of $82 million and an adjusted EBITDA of $36 million. Their efficiency initiatives helped mitigate lower operating leverage and maintain margins, resulting in $30 million in operating cash flow and a cash balance of $162 million, marking the highest in three years. Cresco Labs continued to focus on strategic growth, prioritizing depth over breadth in market expansion, and maintained their leadership position in branded wholesale products, holding the number one market share in Illinois and Pennsylvania. They also reported that Sunnyside dispensaries outperformed, generating approximately 25% more revenue per store than the state average. Looking ahead, they anticipate modest revenue decline in Q2 due to Illinois' seed-to-sale system conversion, with the expectation of sales normalization in future quarters.

Cresco Labs Financial Statement Overview

Summary
Cresco Labs is on a path to recovery with improving margins and cash flows, despite ongoing revenue challenges. The company has shown operational improvements with positive cash flow, though high leverage and declining equity remain concerns. Continued efforts in enhancing operational efficiency and managing debt levels will be crucial for future stability and growth.
Income Statement
45
Neutral
Cresco Labs has experienced a decline in total revenue over the past two years with a revenue decrease from $842.7M in 2022 to $724.3M in 2024. Despite having a strong gross profit margin of 50.3% in 2024, the company faces challenges with sustained net losses, though the net loss has decreased from -$175.5M in 2023 to -$74.4M in 2024. EBIT and EBITDA margins have shown improvement, indicating a potential turnaround in operational efficiency.
Balance Sheet
55
Neutral
The debt-to-equity ratio stands at 1.35 in 2024, reflecting a moderate level of leverage. The equity ratio remains relatively stable at 35.0%, indicating a balanced approach toward asset financing. However, the decline in stockholders' equity from $505.7M in 2023 to $474.9M in 2024 suggests challenges in preserving equity value. Return on equity has improved as net losses have narrowed.
Cash Flow
60
Neutral
Cresco Labs shows an improvement in operating cash flow, increasing from $58.6M in 2023 to $132.5M in 2024, which is a positive sign of better cash management. Free cash flow has also turned positive, reaching $109.0M in 2024, a significant improvement from $0.7M in 2023. This is indicative of stronger operational performance and better capital expenditure management.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
724.34M770.88M842.68M821.68M476.25M
Gross Profit
364.45M362.37M407.01M406.35M283.94M
EBIT
107.29M-87.82M65.75M87.97M58.30M
EBITDA
114.28M-14.36M-10.66M-159.63M5.23M
Net Income Common Stockholders
-74.44M-175.52M-215.84M-296.83M-36.56M
Balance SheetCash, Cash Equivalents and Short-Term Investments
137.56M103.43M119.34M223.54M136.34M
Total Assets
1.36B1.36B1.58B1.78B1.33B
Total Debt
639.64M682.76M670.17M624.74M354.58M
Net Debt
502.08M579.33M550.83M401.19M218.24M
Total Liabilities
967.18M930.40M996.01M982.73M608.37M
Stockholders Equity
474.85M505.69M627.04M755.55M574.45M
Cash FlowFree Cash Flow
108.99M681.00K-67.39M-82.57M-91.21M
Operating Cash Flow
132.48M58.56M18.74M14.49M-10.83M
Investing Cash Flow
-25.23M-44.59M-36.58M-163.93M-44.11M
Financing Cash Flow
-71.48M-26.91M-86.64M235.00M142.67M

Cresco Labs Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.75
Price Trends
50DMA
0.96
Negative
100DMA
1.09
Negative
200DMA
1.49
Negative
Market Momentum
MACD
-0.08
Positive
RSI
35.38
Neutral
STOCH
24.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CL, the sentiment is Negative. The current price of 0.75 is below the 20-day moving average (MA) of 0.90, below the 50-day MA of 0.96, and below the 200-day MA of 1.49, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 35.38 is Neutral, neither overbought nor oversold. The STOCH value of 24.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CL.

Cresco Labs Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.24B3.27-45.39%2.80%16.77%-0.07%
TSCL
51
Neutral
$321.22M-17.34%-4.38%46.68%
$734.45M15.514.61%
$652.44M-25.08%
$1.21B24.682.83%
$753.34M-12.39%
$1.58B-31.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CL
Cresco Labs
0.75
-1.64
-68.62%
CRON
Cronos Group
1.98
-0.51
-20.48%
CURLF
Curaleaf Holdings
0.88
-3.54
-80.09%
GTBIF
Green Thumb Industries
5.20
-6.95
-57.20%
TCNNF
Trulieve Cannabis
3.94
-5.63
-58.83%
VRNOF
Verano Holdings
0.53
-3.23
-85.90%

Cresco Labs Corporate Events

Business Operations and StrategyFinancial Disclosures
Cresco Labs Reports Strong Q1 2025 Financial Results and Strategic Growth Plans
Positive
May 30, 2025

Cresco Labs reported strong financial results for the first quarter of 2025, with a revenue of $166 million and an operating cash flow of $30 million. The company emphasized its strategic approach to reducing credit risk and maintaining financial flexibility, ending the quarter with a cash balance of $162 million, the highest in three years. Cresco Labs aims to drive margin expansion and sustainable growth by deploying capital thoughtfully, positioning itself to gain market share and enhance value for stakeholders.

The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Cresco Labs Updates Q1 2025 Earnings Release Date
Positive
May 29, 2025

Cresco Labs has announced the updated date for its first quarter 2025 earnings release, scheduled for May 30, 2025. The company has completed its financial review with no material changes and plans to discuss the results in a conference call on June 2, 2025. This announcement reflects Cresco Labs’ commitment to transparency and its strategic positioning in the cannabis market, potentially impacting stakeholders positively by reinforcing trust in its financial practices.

The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Cresco Labs Expands in Pennsylvania with New Sunnyside Dispensary
Positive
May 28, 2025

Cresco Labs has announced the opening of a new Sunnyside dispensary in Chippewa Township, Beaver Falls, Pennsylvania, reinforcing its strong market presence in the state. This expansion highlights Cresco Labs’ strategic focus on deepening its core market presence, particularly in Pennsylvania where it holds a leading position in branded market share. The new location aims to enhance patient service with high-quality products and a superior retail experience, potentially increasing operating leverage and strengthening its industry positioning.

The most recent analyst rating on (TSE:CL) stock is a Buy with a C$4.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.

Financial DisclosuresRegulatory Filings and Compliance
Cresco Labs Postpones Q1 2025 Earnings Release
Negative
May 8, 2025

Cresco Labs announced the postponement of its first quarter 2025 earnings release and conference call to allow more time for reviewing its interim financial statements. The rescheduling is expected to have implications for stakeholders as the company aims to maintain transparency and compliance with filing requirements, potentially impacting investor confidence and market perception.

Financial Disclosures
Cresco Labs Postpones Q1 2025 Earnings Release
Negative
May 8, 2025

Cresco Labs has announced the postponement of its first quarter 2025 earnings release and conference call, originally scheduled for May 9, 2025, to allow more time for reviewing its interim financial statements. The company expects to reschedule the call and file the statements by May 30, 2025. This delay may impact stakeholders’ expectations and the company’s operational transparency, but Cresco remains committed to maintaining its industry leadership and stakeholder trust.

Business Operations and StrategyFinancial Disclosures
Cresco Labs Achieves Record Financial Performance in 2024
Positive
Mar 12, 2025

Cresco Labs reported record financial results for 2024, with an operating cash flow of $132 million, marking a 126% increase from the previous year. The company achieved a revenue of $724 million and maintained its leading market share in Illinois, Pennsylvania, and Massachusetts. Despite a net loss of $60 million due to one-time charges, Cresco Labs improved its adjusted EBITDA by 15% year-over-year, reflecting its disciplined strategy and strong market positioning.

Business Operations and Strategy
Cresco Labs Expands into Kentucky’s Medical Cannabis Market
Positive
Mar 10, 2025

Cresco Labs has announced a management services agreement to operate a Tier 3 Cultivation License in Kentucky, marking a significant expansion into the state’s newly launched medical cannabis market. This move positions Cresco Labs as a key player in Kentucky’s burgeoning cannabis industry, with the potential to influence market growth and capitalize on projected revenue increases, reinforcing its strategic expansion and investment in high-return growth opportunities.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.